InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $18.720 0.07 (0.38%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,373 Appendix 4C - quarterly 28 Oct 2011 10:11AM $0.033 $18.720 risen by 56,627.27%
$2,373 Response to ASX Price Query 20 Oct 2011 2:13PM $0.024 $18.720 risen by 77,900%
$2,373 Half Yearly Report and Accounts 30 Aug 2011 9:12AM $0.017 $18.720 risen by 110,017.65%
$2,373 Neuren places $3m of rights issue shortfall 16 Aug 2011 8:54AM $0.016 $18.720 risen by 116,900%
$2,373 Appendix 4C - quarterly 29 Jul 2011 12:05PM $0.017 $18.720 risen by 110,017.65%
$2,373 Neuren Rights Issue Letter of Offer (Australian residents) 15 Jun 2011 8:29AM $0.017 $18.720 risen by 110,017.65%
$2,373 Neuren Rights Issue Offer Document (NZ residents) 15 Jun 2011 8:29AM $0.017 $18.720 risen by 110,017.65%
$2,373 Neuren announces Renounceable Rights Issue 15 Jun 2011 8:27AM $0.017 $18.720 risen by 110,017.65%
$2,373 Neuren reduces outstanding convertible note principal 20 May 2011 2:22PM $0.021 $18.720 risen by 89,042.86%
$2,373 Neuren`s Perseis selects lead antibodies 19 May 2011 10:01AM $0.020 $18.720 risen by 93,500%
$2,373 Neuren Completes Phase II trial Cohort 1 11 May 2011 10:40AM $0.019 $18.720 risen by 98,426.32%
$2,373 Neuren Announces Private Placement and Rights Issue 4 May 2011 9:51AM $0.014 $18.720 risen by 133,614.29%
$2,373 Trading Halt 2 May 2011 10:13AM $0.015 $18.720 risen by 124,700%
$2,373 Appendix 4C - quarterly 29 Apr 2011 1:33PM $0.022 $18.720 risen by 84,990.91%
$2,373 Response to ASX Price Query 10 Mar 2011 9:40AM $0.017 $18.720 risen by 110,017.65%
$2,373 Preliminary Final Report 28 Feb 2011 2:31PM $0.013 $18.720 risen by 143,900%
$2,373 Appendix 4C - quarterly 31 Jan 2011 1:16PM n/a $18.720 n/a
$2,373 Neuren Initiates NNZ2566 Oral Formulation Development 18 Nov 2010 9:41AM $0.019 $18.720 risen by 98,426.32%
$2,373 Neuren Completes Additional Phase I Study for TBI 16 Nov 2010 9:03AM $0.020 $18.720 risen by 93,500%
$2,373 Neuren Completes Additional Phase I Study for TBI 16 Nov 2010 9:03AM $0.020 $18.720 risen by 93,500%
$2,373 Appendix 4C - quarterly 27 Oct 2010 1:48PM $0.019 $18.720 risen by 98,426.32%
$2,373 Half Yearly Report and Accounts 26 Aug 2010 9:22AM $0.018 $18.720 risen by 103,900%
$2,373 Appendix 4C - quarterly 28 Jul 2010 9:27AM $0.023 $18.720 risen by 81,291.30%
$2,373 Neuren Starts Phase II Trial of NNZ2566 6 May 2010 9:55AM $0.032 $18.720 risen by 58,400%
$2,373 Appendix 4C - quarterly 30 Apr 2010 8:53AM $0.032 $18.720 risen by 58,400%

701 - 725 of 833 results

Page 29 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.